Ann: Suspension from Official Quotation, page-43

First 43 Last

Share
Profile

Follow
Devaney01

3 Posts.

17/05/17

12:42

Post #: 24741717
Share

Originally posted by buffetman ↑

Pure speculation hottuna. Could be good, could be bad. We won't find out till next week.

I think a smart move by the company to take the time to respond comprehensively to all the allegations raised and negative short biased reports published as they obviously haven't done a great job of countering these so far.

Plus new CEO will presumably get updated sales forecasts and actuals and compare actuals with what was expected pre all the negative sentiment.

All the activity is currently based on emotion plus some short-biased reports from companies that haven't done a full due diligence and visited the growing sites. Even the credit rating agencies have no doubt jumped on this negative vibe too so they don't risk being caught with their pants down. They've been wrong so many times. Just look at the precursors of the GFC and their ratings on Fannie Mae Freddie Mac etc. and the packaged junk loans.

Consider the due diligence that would've been done on the bond issue. Way more than any of us here who I'd suspect have never visited their operations and Glaucus who haven't either, but they've been smart enticing people to piggy back on their short.

People panicking and selling who don't understand how to value a company and fund managers at year end who live on their performance from quarter to quarter and year to year which often forces their hand to sell good assets for short term figures.

QIN has strong recurring revenues. All the assets are still in place. They have survived for years without any sales. All the grower contracts and recurring revenue streams are still in place. The growing assets are increasing in value day by day.

I would like to see some scenario planning of worst case scenario of operations with zero sales as I suspect there's enough recurring revenue to not be of a concern anyway.

Expand

Thank you, a Very Grounded comment. As a Contractor who works on one of the QIN Plantations, it is surreal to watch all the hysteria whipped up by Glaucus to make money, and then to drive through the very professionally run Plantation and see the beautifully healthy Saldalwood Trees.

QIN Price at posting: 29.5¢ Sentiment: None Disclosure: Not Held
25 Upvote

0 Great analysis

Reply

Top Stories

BNL

Blue Star Helium sees approval for five more wells at 'Galactica/Pegasus' project in Colorado

EEG

NT Gov't delivers environmental approval for Empire Energy's Beetaloo Carpentaria pilot gas play

CUF

CuFe sells its Crossroads gold royalty to Northern Star for $4M cash; says better than waiting for mine launch

GDM

Banshee's historic trenches prove rich in antimony and gold for GDM

3DA

To make modern missiles, you need 3D Printing. And in that gold rush, Amaero is selling shovels

Week 46 Wrap: Copper hits 2mth low as Trump threatens net zero pace; US rally fades; HotCopper’s picks

CLE

Cyclone signs MOU with Vale for development of Iron Bear play

HotCopper Highlights: Your most watched stocks for Week 46, 2024

IRX

InhaleRX gains approval for clinical trial to test non-opioid therapy for cancer pain

BTH

Bigtincan's Board backs Investcorp offer: Why a NASDAQ listing could be game-changing

First 43 Last

Add QIN (ASX) to my watchlist

Ann: Suspension from Official Quotation, page-43

Top Stories

Blue Star Helium sees approval for five more wells at 'Galactica/Pegasus' project in Colorado

NT Gov't delivers environmental approval for Empire Energy's Beetaloo Carpentaria pilot gas play

CuFe sells its Crossroads gold royalty to Northern Star for $4M cash; says better than waiting for mine launch

Banshee's historic trenches prove rich in antimony and gold for GDM

To make modern missiles, you need 3D Printing. And in that gold rush, Amaero is selling shovels

Week 46 Wrap: Copper hits 2mth low as Trump threatens net zero pace; US rally fades; HotCopper’s picks

Cyclone signs MOU with Vale for development of Iron Bear play

HotCopper Highlights: Your most watched stocks for Week 46, 2024

InhaleRX gains approval for clinical trial to test non-opioid therapy for cancer pain

Bigtincan's Board backs Investcorp offer: Why a NASDAQ listing could be game-changing

Featured News